Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

A legfontosabb adatok

Ki végzi
Boehringer Ingelheim
Hol
Edmonton (Kanada)A helyszín megnézéseMég 1 másik országban, 27 helyszínen
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
30 fő, tervezett
Kezdés
2026. febr. 27.
Várható befejezés
2027. aug. 5.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • BI 3802876
  • Placebo
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with compensated liver cirrhosis (scarring that still lets the liver work) caused by MASH, a fatty liver disease linked to metabolism. It tests how well BI 3802876 is tolerated.

Életkor
18 to 75 years
Nem
All sexes
A betegség stádiuma
Compensated MASH cirrhosis, Child-Pugh category A, with no past decompensation event (serious liver failure complications). Diagnosis by liver biopsy, imaging or non-invasive tests, as set out in the record.
Biomarker vagy leletérték
Some routes in need imaging showing liver fat (FibroScan® CAP ≥288 dB/m or MRI-PDFF ≥5%) and at least 2 metabolic conditions, such as obesity or type 2 diabetes.

A részvétel fő kizáró okai

  • Signs of advanced high pressure in the liver veins, such as VCTE ≥30 kPa, varices on endoscopy, or HVPG ≥10 mmHg
  • Other causes of liver disease, including alcohol, autoimmune liver disease, or past or present hepatitis B or C
  • Past liver transplant, being on the transplant list, or liver cancer (HCC) now or in the past
  • MELD score > 12 or INR >1.3, unless due to blood thinners
  • Heavy drinking (> 210 g/week in males, > 140 g/week in females) within 1 year before screening

A regiszter feltételei, szó szerint

Mind a 12 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female adults ≥18 to ≤75 years of age at the time of screening, and at least the legal age of consent in countries where it is > 18 years
  • Patients meeting criteria for Child-Pugh category A without history of previous decompensation event
  • Compensated Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis diagnosed by 1 of the following:; The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatohepatitis. There is no evidence for a competing aetiology; Historical biopsy (≤ 5 years prior to randomisation) showed steatohepatitis with F1 to F3 fibrosis, but now with cirrhosis either by NITs or biopsy. There is no evidence of competing aetiology. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there is at least 1 coexisting or history of metabolic comorbidity; The most recent liver biopsy (≤ 5 years prior to randomisation) showing cirrhosis with steatosis. There are at least 2 coexisting metabolic comorbidities or history of metabolic comorbidities, including obesity and/or type 2 diabetes mellitus (T2DM). There is no evidence for a competing aetiology; Historical biopsy (≤ 5 years prior to randomisation) showed steatosis, but now with cirrhosis, either by NITs or biopsy. If there is a current biopsy (≤ 6 months prior to randomisation), and it does not show evidence of steatosis or steatohepatitis, there are at least 2 coexisting or history of metabolic comorbidities including obesity and/or T2DM. There is no evidence of competing aetiology; Trial participant with cirrhosis with current or previous imaging showing evidence of steatosis (by liver ultrasound or CT scan or FibroScan® with CAP ≥288 dB/m or MRI-PDFF ≥5%). There is no liver histology available. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and/or T2DM. There is no evidence of competing aetiology; Cryptogenic cirrhosis' (either by NITs or biopsy; not to exceed 20% of trial participants) without current or previous evidence of steatosis by imaging or steatosis/steatohepatitis by histology. There are at least 2 coexisting or history of metabolic comorbidities, including obesity and/or T2DM. There is no evidence of competing aetiology; Further inclusion criteria apply

Ki nem vehet részt

  • History of significant alcohol consumption (defined as intake of > 210 g/week in males and > 140 g/week in females on average over a consecutive period of more than 3 months) within 1 year prior to screening
  • Other causes of liver disease based on medical history and/or centralized review of liver histology, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis [PBC], primary sclerosing cholangitis [PSC], autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1- antitryspin deficiency
  • Chronic viral hepatitis parameters that would be considered exclusionary for the participation in this trial are (hepatitis B and C testing will be done at screening visit):; Hepatitis B virus (HBV): Past or present hepatitis B infection, including a positive hepatitis B surface antigen (HBsAg) and/or detectable HBV Deoxyribonucleic Acid (DNA); Hepatitis C virus (HCV): Past or present hepatitis C infection, including positive hepatitis C antibodies and/or detectable HCV ribonucleic acid (RNA)
  • History of liver transplantation or patients listed for liver transplantation
  • Suspicion, confirmed diagnosis, or history of Hepatocellular Carcinoma (HCC)
  • Model for End-Stage Liver Disease (MELD) score > 12, unless due to therapeutic anti-coagulation
  • Patients with clinically significant signs of advanced portal hypertension defined by any of the following:; VCTE ≥30 kPa; VCTE ≥25 kPa and platelets < 150,000/μL; History of esophageal or gastric varices (Grade ≥1) on endoscopy; Hepatic venous pressure gradient (HVPG) ≥10 mmHg
  • International Normalized Ratio (INR) >1.3 unless due to therapeutic anticoagulants or laboratory error Further exclusion criteria apply
  • Present or past evidence of decompensating events of liver cirrhosis

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 75 év között vagy?

Helyszínek itt: Kanada

Még 1 másik országban, 27 helyszínen

  • University of Alberta Hospital (University of Alberta)Edmonton, KanadaContact: Boehringer IngelheimToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH). The purpose of this study is to find out how well a study medicine called BI 3802876 is tolerated in people with this condition. The study looks at how different doses of BI 3802876 are handled by the body. BI 3802876 is being developed to improve liver health in people living with this liver condition.

A teljes eredeti leírásKevesebb

Participants are put in 3 different dose groups randomly, which means by chance. Participants within a group get BI 3802876 or placebo. Placebo looks like BI 3802876 but does not contain any medicine. Participants have more than twice the chance of receiving BI 3802876 than placebo. The study medicine is given as an infusion into a vein.

Participants are in the study for about half a year. During this time, they visit the study site 12 times. At 2 visits, participants get the study medicine. Doctors collect information on any health problems and take blood samples to check how BI 3802876 is handled by the body. They compare results between the groups.

A vizsgálat 4 csoportja

  • Placebo groupPlacebo, összehasonlításként

    Kezelés: Placebo

  • Dose group 1A vizsgált kezelés

    Kezelés: BI 3802876

  • Dose group 2A vizsgált kezelés

    Kezelés: BI 3802876

  • Dose group 3A vizsgált kezelés

    Kezelés: BI 3802876

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase IIa Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 3802876 in Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07325526: ki vehet részt
A regiszteradat frissítve
2026. november 12.